Bicycle Therapeutics PLC

BCYC

5.660USD

+0.350+6.59%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Bicycle Therapeutics PLC's Score

Industry at a Glance

Industry Ranking

51 / 392

Overall Ranking

158 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Bicycle Therapeutics PLC Highlights

StrengthsRisks

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 143.90% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 35.27M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 35.27M.

Overvalued

The company’s latest PE is -1.56, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 39.22M shares, increasing 0.08% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 10.52K shares of this stock.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

20.167

Target Price

+279.79%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Bicycle Therapeutics PLC is 7.79, ranking 76 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 11.73M, representing a year-over-year increase of 338.49%, while its net profit experienced a year-over-year increase of 16.33%.

Score

Industry at a Glance

Previous score

7.79

Change

0



Financials

9.91

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.38

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.12

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.54

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Bicycle Therapeutics PLC is 7.66, ranking 93 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.56, which is -6.18% below the recent high of -1.46 and -438.91% above the recent low of -8.41.

Score

Industry at a Glance

Previous score

7.66

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 51/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Bicycle Therapeutics PLC is 7.86, ranking 264 out of 392 in the Biotechnology & Medical Research industry. The average price target is 16.00, with a high of 44.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

7.86

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Bicycle Therapeutics PLC is 6.34, ranking 264 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 6.91 and the support level at 4.84, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.05

Change

0.29

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Bicycle Therapeutics PLC is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 114.58%, representing a quarter-over-quarter decrease of 9.44%. The largest institutional shareholder is PRFDX, holding a total of 1.38M shares, representing 2.77% of shares outstanding, with 13.79% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Baker Bros. Advisors LP

10.89M

--

Forbion Capital Partners

3.45M

--

Armistice Capital LLC

2.98M

+6.36%

Westfield Capital Management Company, L.P.

2.95M

+6.19%

Invus Public Equities Advisors, LLC

2.01M

--

Long Focus Capital Management LLC

1.42M

+7.70%

T. Rowe Price Associates, Inc.

Star Investors

1.38M

-5.69%

Candriam Luxembourg S.A.

1.35M

+0.05%

Acadian Asset Management LLC

1.31M

+88.20%

Candriam Belgium S.A.

1.17M

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Bicycle Therapeutics PLC is 4.00, ranking 111 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.66. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Bicycle Therapeutics PLC

BCYC

7.34 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment